Patrick Squiban
Boehringer Ingelheim (Germany)(DE)Boehringer Ingelheim (Portugal)(PT)
Publications by Year
Research Areas
Immunotherapy and Immune Responses, Virus-based gene therapy research, CAR-T cell therapy research, Immune Cell Function and Interaction, Lymphoma Diagnosis and Treatment
Most-Cited Works
- → Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: A preliminary study(1997)254 cited
- → Gene-based vaccines and immunotherapeutics(2004)183 cited
- → Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen‐specific immunotherapy in patients with MUC1‐positive advanced cancer(2003)172 cited
- → Phase I Study of Dystrophin Plasmid-Based Gene Therapy in Duchenne/Becker Muscular Dystrophy(2004)149 cited
- → Adenovirus-mediated intralesional interferon-γ gene transfer induces tumor regressions in cutaneous lymphomas(2004)104 cited
- → MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure(2008)80 cited
- → Phase I Trial of Antigen-Specific Gene Therapy Using a Recombinant Vaccinia Virus Encoding MUC-1 and IL-2 in MUC-1-Positive Patients With Advanced Prostate Cancer(2004)74 cited
- → A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma(2003)63 cited
- → Metastatic Breast Tumour Regression Following Treatment by a Gene‐Modified Vaccinia Virus Expressing MUC1 and IL‐2(2003)44 cited
- → Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies(2002)42 cited